Browse News

Found 64 articles

• Nuvalent to Participate in the TD Cowen 4th Annual Oncology Innovation Summit

  5/24/2023

  Nuvalent, Inc. announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in a fireside chat during the TD Cowen 4th Annual Oncology Innovation Summit on Wednesday, May 31, 2023, at 10:30 a.m. ET.

• Nuvalent Announces Anticipated Timing of Preliminary Phase 1 Dose-Escalation Data for NVL-655 and Reports First Quarter 2023 Financial Results

  5/11/2023

  Nuvalent, Inc. announced plans to share preliminary data from the dose-escalation portion of its ongoing ALKOVE-1 Phase 1/2 clinical trial for NVL-655, a novel ALK-selective inhibitor, in the second half of 2023, and reported first quarter 2023 financial results.

• Nuvalent to Participate in the Stifel 2023 Virtual Targeted Oncology Days

  4/19/2023

  Nuvalent, Inc. announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in a fireside chat during the Stifel 2023 Virtual Targeted Oncology Days on Wednesday, April 26, 2023, at 1:30 p.m. ET.

• Nuvalent Presents New Preclinical Data Supporting Intracranial Activity of NVL-655 at AACR Annual Meeting 2023

  4/18/2023

  Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the presentation of new preclinical data supporting the intracranial activity NVL-655.

• Nuvalent to Present ALKOVE-1 Trial in Progress Poster for NVL-655 at the European Lung Cancer Congress (ELCC 2023)

  3/23/2023

  Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, announced an upcoming poster presentation for the ongoing Phase 1/2 ALKOVE-1 study of its ALK-selective inhibitor, NVL-655.

• Nuvalent Highlights Pipeline and Business Progress and Reports Fourth Quarter and Full Year 2022 Financial Results

  3/16/2023

  Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, highlighted pipeline and business progress and fourth quarter and full year 2022 financial results.

• Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2023

  3/14/2023

  Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced an upcoming preclinical data poster presentation supporting the ongoing clinical development of its ALK-selective inhibitor, NVL-655.

• Nuvalent to Participate in the 43rd Annual Cowen Healthcare Conference

  3/1/2023

  Nuvalent, Inc. today announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom , Chief Financial Officer, will participate in a fireside chat during the 43rd Annual Cowen Healthcare Conference on Wednesday, March 8, 2023, at 9:10 a.m. ET in Boston. 

• Nuvalent to Present at the 41st Annual J.P. Morgan Healthcare Conference

  1/4/2023

  Nuvalent, Inc. today announced that James Porter, Ph.D., Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023.

• Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ROS1-selective inhibitor NVL-520

  12/13/2022

  Nuvalent, Inc. (Nasdaq: NUVL) today announced the publication of a manuscript in Cancer Discovery, a journal of the American Association for Cancer Research, which describes the design and characterization of NVL-520 and details Nuvalent's approach to rationally targeting ROS1. 

• Nuvalent Reviews Corporate and Pipeline Achievements and Reports Third Quarter 2022 Financial Results

  11/10/2022

  Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, reported recent business and pipeline progress and third quarter 2022 financial results.

• Nuvalent Announces Closing of Upsized Public Offering of Common Stock - November 04, 2022

  11/4/2022

  Nuvalent, Inc. announced the closing of its previously announced upsized underwritten public offering of 7,895,522 shares of Class A common stock, which includes 1,029,850 shares of Class A common stock sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a price to the public of $33.50 per share.

• Nuvalent Announces Pricing of Public Offering of Common Stock

  11/1/2022

  Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, announced the pricing of its previously announced underwritten public offering of 6,865,672 shares of Class A common stock at a price to the public of $33.50 per share.

• Nuvalent Announces Public Offering of Common Stock

  10/31/2022

  Nuvalent, Inc. today announced that it has commenced an underwritten public offering of $200.0 million of its shares of Class A common stock.

• Nuvalent Reports Preliminary Phase 1 Clinical Data from ARROS-1 Trial that Support Best-In-Class Potential of NVL-520 for Patients withROS1-Positive NSCLC

  10/28/2022

  Nuvalent, Inc. announced the initial data from the Phase 1 dose-escalation portion of its ongoing ARROS-1 Phase 1/2 clinical trial of NVL-520 for patients with advanced ROS1-positive non-small cell lung cancer and other solid tumors.

• Nuvalent Announces New Preclinical Data for Selective Kinase Inhibitors NVL-330 and NVL-655

  10/26/2022

  Nuvalent, Inc. announced the presentation of new preclinical data for NVL-330, its recently nominated HER2-selective inhibitor, and NVL-655, its ALK-selective inhibitor currently under investigation in the ALKOVE-1 Phase 1/2 study for advanced ALK-positive non-small cell lung cancer and other solid tumors.

• Nuvalent to Host Conference Call to Discuss Preliminary Phase 1 Data from ARROS-1 Clinical Trial of NVL-520 and Additional Preclinical Updates in Conjunction with 34th EORTC-NCI-AACR Symposium

  10/17/2022

  Nuvalent, Inc. announced that management will host a live webcast and conference call in conjunction with its data presentations at the 34th EORTC-NCI-AACR Symposium in Barcelona, Spain on Friday, October 28, 2022 at 8:30 a.m. EDT.

• Nuvalent Appoints Michael L. Meyers, MD, PhD, to Board of Directors

  10/6/2022

  Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, announced the appointment of Michael L. Meyers, M.D., Ph.D., to its Board of Directors.

• Nuvalent to Present Preliminary Phase 1 Data from ARROS-1 Clinical Trial of NVL-520 at 34th EORTC-NCI-AACR Symposium and Announces Pipeline Updates

  9/7/2022

  Nuvalent, Inc. announced it will present preliminary dose escalation data from its ongoing ARROS-1 Phase 1/2 clinical trial of NVL-520 for patients with advanced ROS1-positive non-small cell lung cancer and other solid tumors during an oral plenary session at the 34th EORTC-NCI-AACR Symposium taking place October 26-28, 2022 in Barcelona, Spain.

• Nuvalent to Participate in the Wells Fargo 2022 Healthcare Conference

  9/1/2022

  Nuvalent, Inc. announced that James Porter, Ph.D., Chief Executive Officer, will participate in a fireside chat at the Wells Fargo 2022 Healthcare Conference on Thursday, September 8, 2022, at 2:35 p.m. ET in Boston.